We aimed to understand the reasons patients choose to pursue third line overactive bladder (OAB) therapy.
We conducted a mixed methods study that included patient interviews and survey data. Eligible patients were diagnosed by symptoms, had tried behavioral modifications, and OAB medications enrolled from October 2018 to August 2019.